Novavax, Inc. NVAX
today announced that positive clinical data for the company's virus-like
particle (VLP) vaccine candidate against A(H7N9) influenza were published
online in the Correspondence section of The New England Journal of Medicine.
The correspondence can be found at:
http://www.nejm.org/doi/full/10.1056/NEJMc1313186 and will appear in the
December 26, 2013 print edition.
The study, conducted in 284 adult male and female subjects, examined the
safety and immunogenicity of two administrations of Novavax' A(H7N9) VLP
vaccine candidate on day 0 and day 21. Subjects were administered either
placebo, 15 or 45 µg of vaccine alone, or 5 or 15µg of vaccine with either 30
or 60 ISCO^® units of the saponin-based ISCOMATRIX^® adjuvant, developed by
CSL Limited in Australia. Serology was assessed at Days 0, 21 and 35
post-first immunization.
The Novavax A(H7N9) VLP vaccine candidate was generally well tolerated, and
the safety was in line with the company's previous findings with its influenza
VLP antigens using ISCOMATRIX^® adjuvant. Overall, as with other adjuvanted
influenza vaccines, there was an increase in transient local and systemic
reactions in the adjuvanted in contrast to the non-adjuvanted formulations,
but there were no treatment-related SAEs in the active groups. The A(H7N9) VLP
vaccine candidate induced hemagglutination-inhibition (HAI) antibody titers of
≥1:40 (seroprotection) and a four-fold HAI antibody rise (serconversion)
against H7N9 in 81% of subjects at the 5mg dose of A(H7N9) antigen with 60
ISCO^® units of adjuvant, and 73% of subjects receiving 5mg dose of A(H7N9)
antigen with either adjuvant dose level. The vaccine also elicited
anti-neuraminidase (NA) antibodies against N9 in 92 to 97% of subjects
receiving 5mg with either adjuvant dose level.
The A(H7N9) influenza strain has emerged recently as a potential pandemic
concern. Less than ten (10) days after the Chinese Health authorities
announced an outbreak of this novel avian influenza in humans (137 total
confirmed cases, including 45 deaths, to date), Novavax obtained the genetic
sequence of the strain and commenced production of a recombinant vaccine.
Clinical trial material was manufactured and released in late June 2013 with
the first doses injected in humans in early July 2013. Less than four months
after the novel A(H7N9) virus had been identified and sequenced, Novavax' H7N9
VLP vaccine, with the higher-dose of ISCOMATRIX® adjuvant, has achieved immune
responses likely to be protective in 81% of recipient subjects with as little
as 5µg of antigen.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in